orlistat (xenical) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Orlistat or tetrahydrolipstatin (Xenical, Hoffmann-La Roche) is a saturated derivative of lipstatin originally isolated from Streptomyces toxytricini. Orlistat (Xenical, Hoffmann-La Roche) is a powerful inhibitor of gastrointestinal lipase and as such, reduces fat absorption. Orlistat acts by binding covalently to the serine residue of the active site of gastric and pancreatic lipases. When administered with fat-containing foods, orlistat partially inhibits hydrolysis of triglycerides, thus reducing the subsequent absorption of monoaclglycerides and free fatty acids. Unlike other weight-reducing drugs it is minimally absorbed and has no effects in the CNS. Xenical is indicated for obesity management including weight loss and weight maintenance when used in conjunction witha reduced-calorie diet. XENICAL is also indicated to reduce the risk for weight regain after prior weight loss. XENICAL is indicated for obese patients with an initial body mass index (BMI) ≥ 30 kg/m2 or ≥ 27 kg/m2 in the presence of other risk factors (eg, hypertension, diabetes, dyslipidemia). In addition to its well established efficacy in achieving modest weight loss, orlistat has been shown to improve glycaemic parameters in obese adults with type 2 diabetes mellitus as well as some features of the metabolic syndrome.   NCATS

Chemistry

  • SMILES: CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O
  • InChIKey: AHLBNYSZXLDEJQ-FWEHEUNISA-N
  • Mol. Mass: 495.7348
  • ALogP: 6.88
  • ChEMBL Molecule:
    orlistat  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.4273 - $6.9402

Australia

$1.1222
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1-((3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl-2-formamido-4-methylvalerate | alli | beacita | de-120 | glaxosmithkline brand of orlistat | hoffmann-la roche brand of orlistat | lipstatin | l-leucine, n-formyl-, 1-((3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester, (2s-(2alpha(r*),3beta))- | orlipastat | orlipastatum | orlistat | ro-180647002 | ro-180647-002 | roche brand of orlistat | tetrahydrolipastatin | tetrahydrolipstatin | (-)-tetrahydrolipstatin | thlp | xenical

Organizations (67)

Research & Development (66)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (25)

Approved Indications (1)


 

Obesity (approved 1999)

Experimental Indications - Clinical Trial Phases 1-4 (25)


 

Bulimia (Phase 4)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 4)

Fatty Liver (Phase 4)

Glucose Intolerance (Phase 4)

Heart Diseases (Phase 4)

Hepatitis (Phase 4)

Hepatitis C (Phase 4)

Hyperlipoproteinemia Type I (Phase 2)

Hypertension (Phase 2)

Hypertriglyceridemia (Phase 2)

Infertility, Female (Phase 3)

Insulin Resistance (Phase 4)

Lipoproteins (Phase 2)

Macular Degeneration (Phase 2)

Metabolic Diseases (Phase 2)

Metabolic Syndrome (Phase 4)

Metabolism (Phase 2)

Obesity ()

Overweight (Phase 4)

Poisoning (Phase 1/Phase 2)

Polycystic Ovary Syndrome (Phase 4)

Sleep Apnea, Obstructive (Phase 2)

Sleep Apnea Syndromes (Phase 2)

Stomach Diseases (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 55
  • # of Trial Organizations: 66

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue